Amgen funds Fortuna for bringing neural stem cells into the clinic
The Venture Capital department of Amgen has invested in the company, Fortuna Fix, to move autologous neural stem cells into the clinical setting. The funding was series B where regenerative medicine startup Fortuna Fix earned $25 million to develop candidates aimed to target diseases such as Parkinson’s and spinal cord injury. The trials are supposedly targeted to start by next year. The most impressive aspect of these candidates is that the process of developing stem cells includes patient’s own cells and they should be able to administer its cells without immunosuppression.
EOC Pharma bags $32M series B funding for oncology products
Chinese Pharmaceutical company, EOC Pharma, recently earned $32 million in a series B funding, mainly conducted to bring potential blockbuster oncology drugs to China. The company is looking to hand-pick, develop, manufacture and market these products in China. The Shanghai-based biopharma plans to use the funds to advance its lead programs into late-stage development in China with a focus on registration studies. This is a big step in the young company’s efforts to becoming an integrated one-stop shop for development, manufacturing and commercialization. The company has presently 6 products in their development pipeline.With a newly pocketed $32 million series B, EOC Pharma is looking to bring potential blockbuster oncology drugs to China — products that it will have hand-picked, developed, made and marketed, all on the home turf.
